{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T23:23:28Z","timestamp":1749425008015},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1208\/s12249-020-1630-6","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T19:03:57Z","timestamp":1581707037000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate"],"prefix":"10.1208","volume":"21","author":[{"given":"Ka Lai","family":"Yee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne","family":"DiBenedetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sauzanne","family":"Khalilieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Triantafyllou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Helene","family":"Vallee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Fackler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Aubrey","family":"Stoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"1630_CR1","unstructured":"UNAIDS. Global HIV & AIDS statistics - 2019 fact sheet. 2019. Available online: http:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 19 August 2019."},{"key":"1630_CR2","unstructured":"UNAIDS. UNAIDS Data 2018. 2018. Available online: http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/unaids-data-2018_en.pdf. Accessed 19 August 2019."},{"key":"1630_CR3","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. 2018. Available online: https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf. Accessed 19 August 2019."},{"key":"1630_CR4","unstructured":"Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 2018. Available online: https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/PediatricGuidelines.pdf. Accessed 19 August 2019."},{"key":"1630_CR5","unstructured":"Merck Sharp & Dohme Corp. DELSTRIGO\u2122 (doravirine, lamivudine, and tenofovir disoproxil fumarate) Prescribing Information. Merck & Co., Inc., Whitehouse Station, NJ, USA. 2019. Available online: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf. Accessed 4 October 2019."},{"key":"1630_CR6","unstructured":"Merck Sharp & Dohme Corp. PIFELTRO\u2122 (doravirine) Prescribing Information. Merck & Co., Inc., Whitehouse Station, NJ, USA. 2019. Available online: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_pi.pdf. Accessed 4 October 2019."},{"issue":"5","key":"1630_CR7","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","volume":"5","author":"JM Molina","year":"2018","unstructured":"Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5(5):e211\u2013e20.","journal-title":"Lancet HIV"},{"issue":"4","key":"1630_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/ciy540","volume":"68","author":"C Orkin","year":"2019","unstructured":"Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, et al. Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2019;68(4):535\u201344.","journal-title":"Clin Infect Dis"},{"key":"1630_CR9","unstructured":"Molina J-M, Squires KE, Sax P, Cahn P, Lombaard J, DeJesus E, et al. Doravirine (DOR) versus ritonavir-boosted darunavir (DRV+r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD Noninferiority trial. Abstract LBPEB017, 22nd International AIDS Conference, 2018. Available online: http:\/\/www.aids2018.org\/Portals\/4\/File\/AIDS2018_Abstract_book.pdf. Accessed 19 August 2019."},{"key":"1630_CR10","doi-asserted-by":"crossref","unstructured":"Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arast\u00e9h K, Hoffmann C, et al. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. Antiviral Ther. 2019;24(6):425\u201335.","DOI":"10.3851\/IMP3323"},{"issue":"4","key":"1630_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/00498254.2018.1451667","volume":"49","author":"RI Sanchez","year":"2019","unstructured":"Sanchez RI, Fillgrove KL, Yee KL, Liang Y, Lu B, Tatavarti A, et al. Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019;49(4):422\u201332.","journal-title":"Xenobiotica."},{"issue":"2","key":"1630_CR12","doi-asserted-by":"publisher","first-page":"e01364","DOI":"10.1128\/AAC.01364-16","volume":"61","author":"S Khalilieh","year":"2017","unstructured":"Khalilieh S, Yee KL, Sanchez RI, Triantafyllou I, Fan L, Maklad N, et al. Results of a doravirine-atorvastatin drug-drug interaction study. Antimicrob Agents Chemother. 2017;61(2):e01364\u201316.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1630_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40262-016-0458-4","volume":"56","author":"MS Anderson","year":"2017","unstructured":"Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, et al. A two-way steady-state pharmacokinetic interaction study of doravirine (MK-1439) and dolutegravir. Clin Pharmacokinetics. 2017;56(6):661\u20139.","journal-title":"Clin Pharmacokinetics"},{"issue":"4","key":"1630_CR14","doi-asserted-by":"publisher","first-page":"e02492","DOI":"10.1128\/AAC.02492-18","volume":"63","author":"K Bleasby","year":"2019","unstructured":"Bleasby K, Fillgrove KL, Houle R, Lu B, Palamanda J, Newton DJ, et al. In vitro evaluation of the drug interaction potential of doravirine. Antimicrob Agents Chemother. 2019;63(4):e02492\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"1630_CR15","doi-asserted-by":"crossref","unstructured":"Anderson MS, Gilmartin J, Fan L, Yee KL, Kraft WK, Triantafyllou I, et al. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate co-administration. Antivir Ther. 2019;24(6):443\u201350.","DOI":"10.3851\/IMP3324"},{"issue":"6","key":"1630_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40261-017-0512-5","volume":"37","author":"MO Behm","year":"2017","unstructured":"Behm MO, Yee KL, Liu R, Levine V, Panebianco D, Fackler P. The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects. Clin Drug Investig. 2017;37(6):571\u20139.","journal-title":"Clin Drug Investig."},{"key":"1630_CR17","unstructured":"GlaxoSmithKline\/ViiV Healthcare. EPIVIR (lamivudine) Prescribing Information. 2019. Available online: https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Epivir\/pdf\/EPIVIR-PI-PIL.PDF. Accessed 19 August 2019."},{"key":"1630_CR18","unstructured":"Gilead Sciences, Inc. VIREAD\u00ae (tenofovir disproxil fumarate) Prescribing Information. 2018. Available online: http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/viread\/viread_pi.pdf. Accessed 19 August 2019."},{"issue":"11","key":"1630_CR19","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1517\/17425247.2015.1060218","volume":"12","author":"FL Lopez","year":"2015","unstructured":"Lopez FL, Ernest TB, Tuleu C, Gul MO. Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Expert Opin Drug Deliv. 2015;12(11):1727\u201340.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"1630_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2307\/2533558","volume":"53","author":"MG Kenward","year":"1997","unstructured":"Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53(3):983\u201397.","journal-title":"Biometrics."},{"key":"1630_CR21","unstructured":"Food and Drug Administration (FDA). Use of liquids and\/or soft foods as vehicles for drug administration: general considerations for selection and in vitro methods for product quality assessments - guidance for industry. 2018. Available online: https:\/\/www.fda.gov\/media\/114872\/download. Accessed 26 November 2019."},{"key":"1630_CR22","doi-asserted-by":"publisher","first-page":"e02491","DOI":"10.1128\/AAC.02491-18","volume":"63","author":"W Ankrom","year":"2019","unstructured":"Ankrom W, Sanchez RI, Yee KL, Fan L, Mitra P, Wolford D, et al. Investigation of pharmacokinetic interactions between doravirine and elbasvir\/grazoprevir and ledipasvir\/sofosbuvir. Antimicrob Agents Chemother. 2019;63:e02491\u201318(5).","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1630_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3851\/IMP2920","volume":"20","author":"MS Anderson","year":"2015","unstructured":"Anderson MS, Gilmartin J, Cilissen C, De Lepeleire I, van Bortel L, Dockendorf MF, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20(4):397\u2013405.","journal-title":"Antivir Ther"},{"issue":"10","key":"1630_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40261-017-0552-x","volume":"37","author":"SG Khalilieh","year":"2017","unstructured":"Khalilieh SG, Yee KL, Fan L, Liu R, Heber W, Dunzo E, et al. A randomized trial to assess the effect of doravirine on the QTc interval using a single supratherapeutic dose in healthy adult volunteers. Clin Drug Investig. 2017;37(10):975\u201384.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1630_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/BF03258455","volume":"6","author":"JB Angel","year":"1993","unstructured":"Angel JB, Hussey EK, Hall ST, Donn KH, Morris DM, McCormack JP, et al. Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients. Drug Invest. 1993;6(2):70\u20134.","journal-title":"Drug Invest"},{"issue":"2","key":"1630_CR26","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/clpt.2011.225","volume":"91","author":"P Kasirye","year":"2012","unstructured":"Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, et al. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clin Pharmacol Ther. 2012;91(2):272\u201380.","journal-title":"Clin Pharmacol Ther"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-1630-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-020-1630-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-1630-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:09:28Z","timestamp":1613088568000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-020-1630-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1208\/s12249-020-1630-6","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"3 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KLY, ADB, LF, SK, IT, M-HV, PF, SAS, and MI are current or former employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and may own stock and\/or stock options in Merck & Co., Inc., Kenilworth, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"91"}}